WO2022083649A1 - Forme cristalline d'un dérivé pyridazinique - Google Patents

Forme cristalline d'un dérivé pyridazinique Download PDF

Info

Publication number
WO2022083649A1
WO2022083649A1 PCT/CN2021/125043 CN2021125043W WO2022083649A1 WO 2022083649 A1 WO2022083649 A1 WO 2022083649A1 CN 2021125043 W CN2021125043 W CN 2021125043W WO 2022083649 A1 WO2022083649 A1 WO 2022083649A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
crystal form
compound represented
ray powder
powder diffraction
Prior art date
Application number
PCT/CN2021/125043
Other languages
English (en)
Chinese (zh)
Inventor
盛晓红
盛晓霞
Original Assignee
杭州领业医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 杭州领业医药科技有限公司 filed Critical 杭州领业医药科技有限公司
Priority to CN202180069237.3A priority Critical patent/CN116615200A/zh
Publication of WO2022083649A1 publication Critical patent/WO2022083649A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present disclosure generally relates to the field of medicinal chemistry, and more particularly, the present disclosure relates to crystalline forms of pyridazine derivatives.
  • JAK kinase (Janus kinase, JAK) belongs to the intracellular non-receptor tyrosine kinase family, which mediates the signal produced by cytokines and transmits it through the JAK-STAT signaling pathway.
  • Tyrosine kinase 2 (TYK2), a member of the JAK family, plays an important role in mediating the signaling of pro-inflammatory cytokines, including IL-12, IL-23, and type I interferons.
  • Deucravicitinib is a novel, selective TYK2 inhibitor, a class of pyridazine derivatives, currently in clinical studies for the treatment of a broad range of immune-mediated diseases.
  • the present disclosure relates to Form I of the compound of formula (I):
  • the X-ray powder diffraction pattern (XRPD) of the crystal form I expressed at 2 ⁇ angle has the following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2 ° and 23.2 ⁇ 0.2°.
  • the X-ray powder diffraction pattern represented by the 2 ⁇ angle of the crystal form I has the following characteristic peaks: about 8.2°, about 11.3°, about 19.3°, about 20.5° and about 23.2°.
  • the X-ray powder diffraction pattern of the crystal form I expressed at 2 ⁇ angle has the following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2° ⁇ 0.2°, and the X-ray powder diffraction pattern of the crystalline form I also has characteristic peaks at at least three of the following 2 ⁇ angles: 6.4 ⁇ 0.2°, 10.1 ⁇ 0.2°, 12.6 ⁇ 0.2°, 14.5 ⁇ 0.2°, 16.3 ⁇ 0.2° and 16.4 ⁇ 0.2°.
  • the present disclosure relates to the crystalline form I of the compound represented by formula (I):
  • the X-ray powder diffraction pattern of the crystal form I in 2 ⁇ angle has the following characteristic peaks: about 8.2°, about 11.3°, about 19.3°, about 20.5° and about 23.2°, and all
  • the X-ray powder diffraction pattern of Form I also has characteristic peaks at at least three of the following 2 ⁇ angles: about 6.4°, about 10.1°, about 12.6°, about 14.5°, about 16.3°, and about 16.4°.
  • the X-ray powder diffraction pattern of the crystal form I expressed at 2 ⁇ angle has the following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2° ⁇ 0.2°, and the X-ray powder diffraction pattern of the crystalline form I also has characteristic peaks at the following 2 ⁇ angles: 6.4 ⁇ 0.2°, 10.1 ⁇ 0.2°, 12.60 ⁇ 0.2°, 14.5 ⁇ 0.2°, 16.3 ⁇ 0.2° and 16.4 ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form I in 2 ⁇ angle has the following characteristic peaks: about 8.2°, about 11.3°, about 19.3°, about 20.5° and about 23.2°, and all The X-ray powder diffraction pattern of Form I also has characteristic peaks at the following 2 ⁇ angles: about 6.4°, about 10.1°, about 12.6°, about 14.5°, about 16.3° and about 16.4°.
  • the present disclosure relates to the crystalline form I of the compound represented by formula (I):
  • the X-ray powder diffraction pattern of the crystal form I expressed at 2 ⁇ angle has the following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2° ⁇ 0.2°, and the X-ray powder diffraction pattern of the crystalline form I also has characteristic peaks at at least three of the following 2 ⁇ angles: 14.8 ⁇ 0.2°, 18.3 ⁇ 0.2°, 18.5 ⁇ 0.2°, 19.9 ⁇ 0.2°, 21.5 ⁇ 0.2°, 24.3 ⁇ 0.2°, 25.0 ⁇ 0.2° and 27.8 ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form I in 2 ⁇ angle has the following characteristic peaks: about 8.2°, about 11.3°, about 19.3°, about 20.5° and about 23.2°, and all The X-ray powder diffraction pattern of Form I also has characteristic peaks at at least three of the following 2 ⁇ angles: about 14.8°, about 18.3°, about 18.5°, about 19.9°, about 21.5°, about 24.3°, about 25.0 ° and about 27.8°.
  • the X-ray powder diffraction pattern of the crystal form I expressed at 2 ⁇ angle has the following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2° ⁇ 0.2°, and the X-ray powder diffraction pattern of the crystalline form I also has characteristic peaks at the following 2 ⁇ angles: 18.3 ⁇ 0.2°, 18.5 ⁇ 0.2°, 19.9 ⁇ 0.2°, 21.5 ⁇ 0.2°, 24.3 ⁇ 0.2° , 25.0 ⁇ 0.2° and 27.8 ⁇ 0.2°.
  • the present disclosure relates to the crystalline form I of the compound represented by formula (I):
  • the X-ray powder diffraction pattern of the crystal form I in 2 ⁇ angle has the following characteristic peaks: about 8.2°, about 11.3°, about 19.3°, about 20.5° and about 23.2°, and all The X-ray powder diffraction pattern of Form I also has characteristic peaks at the following 2 ⁇ angles: about 18.3°, about 18.5°, about 19.9°, about 21.5°, about 24.3°, about 25.0°, and about 27.8°.
  • the characteristic peaks of the X-ray powder diffraction pattern of the crystal form I represented by the angle of 2 ⁇ and its relative intensity are about:
  • the crystal form I basically has an X-ray powder diffraction pattern as shown in FIG. 1 .
  • the present disclosure relates to a substantially solvent-free crystalline form I of the compound of formula (I), wherein, using Cu-K ⁇ radiation, the crystalline form I has an X-ray powder diffraction pattern at 2 ⁇ angles Has the following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2 ⁇ 0.2°.
  • the present disclosure relates to a substantially water-free crystalline form I of the compound of formula (I), wherein, using Cu-K ⁇ radiation, the crystalline form I has an X-ray powder diffraction pattern expressed at 2 theta angle having The following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2 ⁇ 0.2°.
  • the present disclosure relates to substantially pure Form I of the compound of formula (I), wherein, using Cu-K ⁇ radiation, the X-ray powder diffraction pattern of Form I in 2 ⁇ angles has the following Characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2 ⁇ 0.2°.
  • the present disclosure relates to a solvent-free and water-free crystalline form I of the compound of formula (I), wherein, using Cu-K ⁇ radiation, X-ray powder diffraction of the crystalline form I in 2 ⁇ angles
  • the spectrum has the following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2 ⁇ 0.2°.
  • the present disclosure relates to a method for preparing the crystal form I of the compound represented by formula (I), which comprises dissolving the compound represented by formula (I) in a halohydrin solvent, concentrating to obtain a solid, and dissolving the compound represented by formula (I) in a halogenated alcohol solvent.
  • the solid is dried to obtain the crystal form I, wherein, using Cu-K ⁇ radiation, the X-ray powder diffraction pattern of the crystal form I represented by the 2 ⁇ angle has the following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2 ⁇ 0.2°.
  • the present disclosure relates to a method for preparing a crystalline form I of a compound of formula (I), comprising in a solution of an acid salt of the compound of formula (I), using a base to free out formula (I)
  • the compound is obtained as a solid, and the solid is isolated, dried, and kept at 120 to 180° C. to obtain the crystal form I, wherein, using Cu-K ⁇ radiation, X-ray powder diffraction of the crystal form I in 2 ⁇ angles
  • the spectrum has the following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2 ⁇ 0.2°.
  • the present disclosure relates to the crystalline form II of the compound represented by formula (II),
  • the X-ray powder diffraction pattern of the crystal form II at 2 ⁇ angle has the following characteristic peaks: 3.3 ⁇ 0.2°, 5.7 ⁇ 0.2°, 8.6 ⁇ 0.2°, 11.8 ⁇ 0.2°, 14.2 ⁇ 0.2° and 18.2 ⁇ 0.2°.
  • the present disclosure relates to the crystalline form II of the compound represented by formula (II),
  • the X-ray powder diffraction pattern of the crystal form II at 2 ⁇ angle has the following characteristic peaks: about 3.3°, about 5.7°, about 8.6°, about 11.8°, about 14.2° and about 18.2° °.
  • the present disclosure relates to the crystalline form II of the compound represented by formula (II),
  • the X-ray powder diffraction pattern of the crystal form II at 2 ⁇ angle has the following characteristic peaks: 3.3 ⁇ 0.2°, 5.7 ⁇ 0.2°, 8.6 ⁇ 0.2°, 11.8 ⁇ 0.2°, 14.2 ⁇ 0.2°, 14.9 ⁇ 0.2°, 16.3 ⁇ 0.2°, 17.3 ⁇ 0.2°, 18.2 ⁇ 0.2°, 20.4 ⁇ 0.2°, 21.5 ⁇ 0.2° and 23.6 ⁇ 0.2°.
  • the present disclosure relates to the crystalline form II of the compound represented by formula (II),
  • the X-ray powder diffraction pattern of the crystal form II at 2 ⁇ angle has the following characteristic peaks: about 3.3°, about 5.7°, about 8.6°, about 11.8°, about 14.2°, about 14.9°, about 16.3°, about 17.3°, about 18.2°, about 20.4°, about 21.5°, and about 23.6°.
  • the present disclosure relates to the crystalline form II of the compound represented by formula (II),
  • the X-ray powder diffraction pattern of the crystal form II at 2 ⁇ angle has the following characteristic peaks: 3.3 ⁇ 0.2°, 5.7 ⁇ 0.2°, 6.5 ⁇ 0.2°, 8.6 ⁇ 0.2°, 11.3 ⁇ 0.2°, 11.8 ⁇ 0.2°, 14.2 ⁇ 0.2°, 14.9 ⁇ 0.2°, 16.3 ⁇ 0.2°, 17.3 ⁇ 0.2°, 18.2 ⁇ 0.2°, 19.9 ⁇ 0.2°, 20.4 ⁇ 0.2°, 21.5 ⁇ 0.2°, 23.6 ⁇ 0.2°, 24.8 ⁇ 0.2° and 26.0 ⁇ 0.2°.
  • the present disclosure relates to the crystalline form II of the compound represented by formula (II),
  • the X-ray powder diffraction pattern of the crystal form II at 2 ⁇ angle has the following characteristic peaks: about 3.3°, about 5.7°, about 6.5°, about 8.6°, about 11.3°, about 11.8°, about 14.2°, about 14.9°, about 16.3°, about 17.3°, about 18.2°, about 19.9°, about 20.4°, about 21.5°, about 23.6°, about 24.8°, and about 26.0°.
  • the present disclosure relates to the crystalline form II of the compound represented by formula (II),
  • the characteristic peaks and relative intensities of the X-ray powder diffraction pattern of the crystal form II represented by the angle of 2 ⁇ are about:
  • the present disclosure relates to the crystalline form II of the compound represented by formula (II),
  • the crystal form II basically has an X-ray powder diffraction pattern as shown in FIG. 5 .
  • the present disclosure relates to substantially pure crystalline Form II of the compound of formula (II), wherein, using Cu-K ⁇ radiation, the crystalline Form II has an X-ray powder diffraction pattern at 2 theta having the following Characteristic peaks: 3.3 ⁇ 0.2°, 5.7 ⁇ 0.2°, 8.6 ⁇ 0.2°, 11.8 ⁇ 0.2°, 14.2 ⁇ 0.2° and 18.2 ⁇ 0.2°.
  • the present disclosure relates to a method for preparing the crystal form II of the compound represented by formula (II), which comprises mixing a solution containing the compound represented by formula (I) with an antisolvent to obtain a solid, and separating the solid, Drying to obtain the crystal form II, wherein, using Cu-K ⁇ radiation, the X-ray powder diffraction pattern of the crystal form II at 2 ⁇ angle has the following characteristic peaks: 3.3 ⁇ 0.2°, 5.7 ⁇ 0.2°, 8.6 ⁇ 0.2°, 11.8 ⁇ 0.2°, 14.2 ⁇ 0.2° and 18.2 ⁇ 0.2°.
  • the present disclosure relates to a method for preparing the crystal form II of the compound represented by the formula (II), which comprises dissolving the compound represented by the formula (I) in a mixed solvent of an organic solvent and water to form a solution, and cooling the compound The solution obtains a solid, and the solid is separated and dried to obtain the crystal form II, wherein, using Cu-K ⁇ radiation, the X-ray powder diffraction pattern of the crystal form II at 2 ⁇ angle has the following characteristic peaks: 3.3 ⁇ 0.2°, 5.7 ⁇ 0.2°, 8.6 ⁇ 0.2°, 11.8 ⁇ 0.2°, 14.2 ⁇ 0.2° and 18.2 ⁇ 0.2°.
  • the present disclosure relates to a method for preparing the crystal form II of the compound represented by formula (II), which comprises stirring an aqueous suspension of the compound represented by formula (I), filtering and drying to obtain the crystal form II,
  • a method for preparing the crystal form II of the compound represented by formula (II) which comprises stirring an aqueous suspension of the compound represented by formula (I), filtering and drying to obtain the crystal form II,
  • the X-ray powder diffraction pattern of the crystal form II at 2 ⁇ angle has the following characteristic peaks: 3.3 ⁇ 0.2°, 5.7 ⁇ 0.2°, 8.6 ⁇ 0.2°, 11.8 ⁇ 0.2°, 14.2 ⁇ 0.2° and 18.2 ⁇ 0.2°.
  • the present disclosure relates to a pharmaceutical composition
  • a pharmaceutical composition comprising crystal form I of the compound represented by formula (I) of the present disclosure, crystal form II of the compound represented by formula (II) of the present disclosure, or formula (II) of the present disclosure I) Any mixture of the crystal form I of the compound represented by the formula (II) of the present disclosure and the crystal form II of the compound represented by the formula (II) of the present disclosure, and a pharmaceutically acceptable carrier, diluent or excipient.
  • the present disclosure relates to a method of treating or preventing a disease or disease state associated with tyrosine kinase 2, comprising administering to an individual in need of the method a therapeutically or prophylactically effective amount of formula (I) of the present disclosure
  • a therapeutically or prophylactically effective amount of formula (I) of the present disclosure comprising administering to an individual in need of the method a therapeutically or prophylactically effective amount of formula (I) of the present disclosure
  • the crystal form I of the compound represented by the formula (II) of the present disclosure or the crystal form I of the compound represented by the formula (I) of the present disclosure and the compound represented by the formula (II) of the present disclosure Any mixture of the crystalline Form II, or a therapeutically effective amount of the pharmaceutical composition of the present disclosure.
  • Fig. 1 shows the X-ray powder diffraction pattern of the crystal form I of the compound represented by formula (I) in an embodiment of the present disclosure
  • Fig. 2 shows the differential scanning calorimetry (DSC) curve of the crystal form I of the compound represented by formula (I) in an embodiment of the present disclosure
  • Fig. 3 shows the thermogravimetric analysis (TGA) curve of the crystal form I of the compound represented by formula (I) in an embodiment of the present disclosure
  • FIG. 5 shows the X-ray powder diffraction pattern of the crystal form II of the compound represented by formula (II) in an embodiment of the present disclosure.
  • Fig. 6 shows the differential scanning calorimetry (DSC) curve of the crystal form II of the compound represented by formula (II) in an embodiment of the present disclosure
  • Fig. 7 shows the thermogravimetric analysis (TGA) curve of the crystal form II of the compound represented by formula (II) in an embodiment of the present disclosure
  • FIG. 8 shows a comparison diagram of long-term and accelerated open-placed X-ray powder diffraction patterns of the crystal form I of the compound represented by formula (I) in an embodiment of the present disclosure
  • FIG. 9 shows a comparison diagram of the long-term and accelerated open-placed X-ray powder diffraction patterns of the crystal form II of the compound represented by formula (II) in an embodiment of the present disclosure
  • Figure 10 shows the results of the competition experiment between the crystal form A obtained in Preparation Example 1 of the present disclosure and the crystal form II of the compound represented by the formula (II) prepared in Example 3;
  • FIG 11 shows a particle size distribution (PSD) diagram of the crystal form I of the compound represented by formula (I) in an embodiment of the present disclosure.
  • FIG. 12 shows a particle size distribution (PSD) graph of the crystal form II of the compound represented by formula (II) in an embodiment of the present disclosure.
  • PSD particle size distribution
  • a pharmaceutical composition comprising "a pharmaceutically acceptable carrier, diluent or excipient” includes one pharmaceutically acceptable carrier, diluent or excipient, or two or more pharmaceutically acceptable carriers, diluents or excipients carrier, diluent or excipient.
  • compound of formula (I) refers to 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4- Triazol-3-yl)anilino]-N-(trideuteromethyl)pyridazine-3-carboxamide, the chemical generic name is Deucravicitinib, and its structural formula is as follows:
  • compound of formula (II) refers to 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4- Triazol-3-yl)anilino]-N-(trideuteromethyl)pyridazine-3-carboxamide dihydrate, namely Deucravicitinib dihydrate, its structural formula is as follows:
  • crystalline form refers to a compound having a uniquely ordered molecular arrangement or configuration within a crystal lattice as evidenced by X-ray powder diffraction pattern characterization.
  • peak positions 2 ⁇
  • peak positions 2 ⁇
  • relative peak intensities can reveal inter-instrument variability as well as variability due to crystallinity, preferred orientation, the surface of the sample prepared, and other factors known to those skilled in the art. , and should only be considered qualitative measurements.
  • the term "2 ⁇ value” or "2 ⁇ ” refers to the peak position in degrees based on an experimental setup of X-ray powder diffraction experiments and is the common abscissa unit for diffraction patterns.
  • the experimental setup requires that if the reflection is diffracted when the incident beam forms an angle ⁇ ( ⁇ ) with a certain crystal plane, the reflected beam is recorded at an angle 2 ⁇ (2 ⁇ ).
  • ⁇ angle
  • 2 ⁇ 2 ⁇ value
  • the term “substantially pure” refers to both chemical and crystalline purity. In certain embodiments, when “substantially pure” is used to refer to a new crystalline form, it means that the new crystalline form constitutes at least 80% by weight of the compound present, more preferably at least 90% by weight, especially At least 95% by weight, especially at least 99% by weight.
  • substantially free means containing no more than about 20% by weight.
  • substantially free of solvent means containing no more than about 20% by weight of solvent.
  • substantially free of water means containing not more than 20% by weight of water.
  • mammals are meant to include animals such as dogs, cats, cows, sheep, horses, humans, and the like. In certain embodiments, mammals include humans.
  • the term "patient” refers to animals (eg, humans), companion animals (eg, dogs, cats, or horses), and livestock (eg, cows, pigs, and sheep).
  • the patient is a mammal including both males and females.
  • the patient is a human.
  • the term "pharmaceutically acceptable” refers to a carrier, vehicle, diluent, excipient and/or salt that must be compatible with the other ingredients of the formulation and not deleterious to its recipient.
  • the term "pharmaceutically acceptable carrier, diluent, or excipient” includes, but is not limited to, any adjuvant, carrier, excipient that has been approved by the US Food and Drug Administration for use in humans or animals , glidants, sweeteners, diluents, preservatives, dyes/colorants, flavor enhancers, surfactants, wetting agents, dispersing agents, suspending agents, stabilizers, isotonic agents, solvents or emulsifiers Agents, etc., are various forms of carriers that have no adverse effects on the composition of the pharmaceutical composition.
  • carrier is defined as a compound that facilitates introduction of a crystalline form of the compound into a cell or tissue.
  • Dimethyl sulfoxide (DMSO) for example, is often used as a carrier because it facilitates the introduction of certain organic compounds into cells or tissues of an organism.
  • the term "pharmaceutical composition” refers to a formulation of Form I of a compound described in this disclosure with a medium generally accepted in the art for the delivery of biologically active compounds to mammals such as humans.
  • Such media include all pharmaceutically acceptable carriers, diluents or excipients.
  • the term "therapeutically effective amount” refers to a formula (I ) of the compound represented by the crystalline form I (or the crystalline form II of the compound represented by the formula (II) or the crystalline form I of the compound represented by the formula (I) and the crystalline form II of the compound represented by the formula (II) any mixture) or the combination of the crystal form I of the compound represented by the formula (I) (or the combination of the crystal form II of the compound represented by the formula (II) or the crystal form I and the formula (II) of the compound represented by the formula (I) any mixture combination of Form II of the compound shown).
  • crystal form I of the compound represented by the formula (I) (or the crystal form II of the compound represented by the formula (II) or the crystal form I of the compound represented by the formula (I) and the compound represented by the formula (II) Form II), the disease state and its severity, and the age, weight, etc.
  • the amount of I (or Form II of the compound of Formula (II) or any mixture of Form I of the compound of Formula (I) and Form II of the compound of Formula (II)) will vary However, those skilled in the art can routinely determine the crystal form I of the compound represented by formula (I) (or the crystal form of the compound represented by formula (II) described in the present disclosure according to their own knowledge and the present disclosure. II or any mixture of the crystalline form I of the compound represented by the formula (I) and the crystalline form II of the compound represented by the formula (II).
  • prophylactically effective amount refers to an amount sufficient to prevent a disease or disease state, or prevent the recurrence thereof.
  • Crystal form I of the compound represented by formula (I) or crystal form II of the compound represented by formula (II) or crystal form I of the compound represented by formula (I) and crystal form of the compound represented by formula (II) A prophylactically effective amount of any mixture of II refers to the amount of a therapeutic agent, alone or in combination with other agents, that provides a prophylactic benefit in preventing a disease or disease state.
  • prophylactically effective amount can include an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
  • treating encompasses treating a related disease or disease state in a mammal, such as a human, afflicted with a related disease or disorder, and includes:
  • disease and “disease state” may be used interchangeably or may be different because a particular disease or disease state may have no known causative agent (and therefore cannot be explained by etiology). ), so it is not recognized as a disease, but as an undesired disease state or disorder in which a clinician has identified a more or less specific set of symptoms.
  • physiologically acceptable refers to a carrier or diluent that does not abrogate the biological activity and properties of the compound.
  • room temperature refers to 10 to 30°C.
  • concentration refers to a method of reducing the volume of a solvent by adjusting temperature, air pressure or gas flow, and the like.
  • the present disclosure relates to Form I of the compound of formula (I):
  • the X-ray powder diffraction pattern of the crystal form I expressed at 2 ⁇ angle has the following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2° ⁇ 0.2°.
  • the X-ray powder diffraction pattern represented by the 2 ⁇ angle of the crystal form I has the following characteristic peaks: about 8.2°, about 11.3°, about 19.3°, about 20.5° and about 23.2°.
  • the X-ray powder diffraction pattern of the crystal form I expressed at 2 ⁇ angle has the following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2° ⁇ 0.2°, and the X-ray powder diffraction pattern of the crystalline form I also has characteristic peaks at at least three of the following 2 ⁇ angles: 6.4 ⁇ 0.2°, 10.1 ⁇ 0.2°, 12.6 ⁇ 0.2°, 14.5 ⁇ 0.2°, 16.3 ⁇ 0.2° and 16.4 ⁇ 0.2°.
  • the present disclosure relates to the crystalline form I of the compound represented by formula (I):
  • the X-ray powder diffraction pattern of the crystal form I in 2 ⁇ angle has the following characteristic peaks: about 8.2°, about 11.3°, about 19.3°, about 20.5° and about 23.2°, and all
  • the X-ray powder diffraction pattern of Form I also has characteristic peaks at at least three of the following 2 ⁇ angles: about 6.4°, about 10.1°, about 12.6°, about 14.5°, about 16.3°, and about 16.4°.
  • the X-ray powder diffraction pattern of the crystal form I expressed at 2 ⁇ angle has the following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2° ⁇ 0.2°, and the X-ray powder diffraction pattern of the crystalline form I also has characteristic peaks at the following 2 ⁇ angles: 6.4 ⁇ 0.2°, 10.1 ⁇ 0.2°, 12.60 ⁇ 0.2°, 14.5 ⁇ 0.2°, 16.3 ⁇ 0.2° and 16.4 ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form I in 2 ⁇ angle has the following characteristic peaks: about 8.2°, about 11.3°, about 19.3°, about 20.5° and about 23.2°, and all The X-ray powder diffraction pattern of Form I also has characteristic peaks at the following 2 ⁇ angles: about 6.4°, about 10.1°, about 12.6°, about 14.5°, about 16.3° and about 16.4°.
  • the present disclosure relates to the crystalline form I of the compound represented by formula (I):
  • the X-ray powder diffraction pattern of the crystal form I expressed at 2 ⁇ angle has the following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2° ⁇ 0.2°, and the X-ray powder diffraction pattern of the crystalline form I also has characteristic peaks at at least three of the following 2 ⁇ angles: 14.8 ⁇ 0.2°, 18.3 ⁇ 0.2°, 18.5 ⁇ 0.2°, 19.9 ⁇ 0.2°, 21.5 ⁇ 0.2°, 24.3 ⁇ 0.2°, 25.0 ⁇ 0.2° and 27.8 ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form I in 2 ⁇ angle has the following characteristic peaks: about 8.2°, about 11.3°, about 19.3°, about 20.5° and about 23.2°, and all The X-ray powder diffraction pattern of Form I also has characteristic peaks at at least three of the following 2 ⁇ angles: about 14.8°, about 18.3°, about 18.5°, about 19.9°, about 21.5°, about 24.3°, about 25.0 ° and about 27.8°.
  • the X-ray powder diffraction pattern of the crystal form I expressed at 2 ⁇ angle has the following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2° ⁇ 0.2°, and the X-ray powder diffraction pattern of the crystalline form I also has characteristic peaks at the following 2 ⁇ angles: 18.3 ⁇ 0.2°, 18.5 ⁇ 0.2°, 19.9 ⁇ 0.2°, 21.5 ⁇ 0.2°, 24.3 ⁇ 0.2° , 25.0 ⁇ 0.2° and 27.8 ⁇ 0.2°.
  • the present disclosure relates to the crystalline form I of the compound represented by formula (I):
  • the X-ray powder diffraction pattern of the crystal form I in 2 ⁇ angle has the following characteristic peaks: about 8.2°, about 11.3°, about 19.3°, about 20.5° and about 23.2°, and all The X-ray powder diffraction pattern of Form I also has characteristic peaks at the following 2 ⁇ angles: about 18.3°, about 18.5°, about 19.9°, about 21.5°, about 24.3°, about 25.0°, and about 27.8°.
  • the characteristic peaks of the X-ray powder diffraction pattern of the crystal form I represented by the angle of 2 ⁇ and its relative intensity are about:
  • the crystal form I basically has an X-ray powder diffraction pattern as shown in FIG. 1 .
  • Form I of the compound of formula (I) has an X-ray powder diffraction pattern that exhibits at least one characteristic peak substantially as shown in the X-ray powder diffraction pattern of FIG. 1 .
  • Form I of the compound of formula (I) has an X-ray powder diffraction pattern exhibiting at least two characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 1 .
  • Form I of the compound of formula (I) has an X-ray powder diffraction pattern exhibiting at least three characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 1 .
  • Form I of the compound of formula (I) has an X-ray powder diffraction pattern exhibiting at least four characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 1 .
  • Form I of the compound of Formula (I) has an X-ray powder diffraction pattern exhibiting at least five characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 1 .
  • Form I of the compound of formula (I) has an X-ray powder diffraction pattern exhibiting at least six characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 1 .
  • Form I of the compound of Formula (I) has an X-ray powder diffraction pattern exhibiting at least seven characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 1 .
  • Form I of the compound of Formula (I) has an X-ray powder diffraction pattern exhibiting at least eight characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 1 .
  • Form I of the compound of Formula (I) has an X-ray powder diffraction pattern exhibiting at least nine characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 1 .
  • Form I of the compound of Formula (I) has an X-ray powder diffraction pattern exhibiting at least ten characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 1 .
  • Form I of the compound of formula (I) has an X-ray powder diffraction pattern exhibiting at least eleven characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 1 .
  • Form I of the compound of formula (I) has an X-ray powder diffraction pattern exhibiting at least twelve characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 1 .
  • Form I of the compound of formula (I) has an X-ray powder diffraction pattern exhibiting at least thirteen peaks characteristic of the X-ray powder diffraction pattern substantially as shown in FIG. 1 .
  • Form I of the compound of formula (I) has an X-ray powder diffraction pattern exhibiting at least fourteen peaks characteristic of the X-ray powder diffraction pattern substantially as shown in FIG. 1 . .
  • Form I of the compound of formula (I) has an X-ray powder diffraction pattern exhibiting at least fifteen peaks characteristic of the X-ray powder diffraction pattern substantially as shown in FIG. 1 . .
  • Form I of the compound of formula (I) has an X-ray powder diffraction pattern exhibiting at least sixteen peaks characteristic of the X-ray powder diffraction pattern substantially as shown in FIG. 1 .
  • Form I of the compound of formula (I) has an X-ray powder diffraction pattern exhibiting at least seventeen peaks characteristic of the X-ray powder diffraction pattern substantially as shown in FIG. 1 .
  • Form I of the compound of formula (I) has an X-ray powder diffraction pattern exhibiting at least eighteen peaks substantially characteristic of the X-ray powder diffraction pattern as shown in FIG. 1 .
  • Form I of the compound of formula (I) has an X-ray powder diffraction pattern that exhibits at least nineteen peaks characteristic of the X-ray powder diffraction pattern substantially as shown in FIG. 1 . .
  • Form I of the compound of Formula (I) has an X-ray powder diffraction pattern that exhibits at least twenty characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 1 . .
  • Form I of the compound of formula (I) has an X-ray powder diffraction exhibiting at least twenty one characteristic peaks in the X-ray powder diffraction pattern substantially as shown in FIG. 1 Atlas.
  • Form I of the compound of formula (I) has an X-ray powder diffraction exhibiting at least twenty-two characteristic peaks in the X-ray powder diffraction pattern substantially as shown in FIG. 1 . Atlas.
  • Form I of the compound of formula (I) has an X-ray powder diffraction exhibiting at least twenty three characteristic peaks in the X-ray powder diffraction pattern substantially as shown in FIG. 1 Atlas.
  • Form I of the compound of formula (I) has an endothermic peak at 259 ⁇ 3°C when thermally analyzed using differential scanning calorimetry (DSC).
  • Form I of the compound of formula (I) has an endothermic peak at 259 ⁇ 1°C when thermally analyzed using differential scanning calorimetry (DSC).
  • Form I of the compound of formula (I) has an endothermic peak at about 259°C when thermally analyzed using differential scanning calorimetry (DSC).
  • the crystalline form I of the compound of formula (I) has at 259 ⁇ 3°C endothermic peak.
  • the crystalline form I of the compound of formula (I) has at 259 ⁇ 1°C endothermic peak.
  • the crystalline form I of the compound of formula (I) exhibits adsorption at about 259°C heat peak.
  • the crystalline Form I of the compound of formula (I) has a melting point of 259 ⁇ 3°C.
  • Form I of the compound of formula (I) has substantially the DSC curve shown in FIG. 2 when thermally analyzed using differential scanning calorimetry (DSC).
  • the crystalline form I of the compound of formula (I) has substantially as shown in FIG. 2 DSC curve shown.
  • Form I of the compound of formula (I) has substantially the TGA curve shown in FIG. 3 when thermally analyzed using thermogravimetric analysis (TGA).
  • thermogravimetric analysis when thermal analysis is performed using thermogravimetric analysis (TGA), at a heating rate of 10° C./min, the crystalline form I of the compound of formula (I) has substantially the form shown in FIG. 3 . TGA curve.
  • thermogravimetric analysis TGA
  • TGA thermogravimetric analysis
  • Form I of the compound of formula (I) has substantially the DVS curve shown in FIG. 4 when analyzed using dynamic moisture adsorption (DVS).
  • Form I of the compound of formula (I) exhibits less than 0.03% weight change over the range of 0 to 80% relative humidity when analyzed using Dynamic Moisture Sorption (DVS) and is not hygroscopic .
  • the present disclosure relates to a substantially solvent-free crystalline form I of the compound of formula (I), wherein, using Cu-K ⁇ radiation, the crystalline form I has an X-ray powder diffraction pattern at 2 ⁇ angles Has the following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2 ⁇ 0.2°.
  • the present disclosure relates to a substantially water-free crystalline form I of the compound of formula (I), wherein, using Cu-K ⁇ radiation, the crystalline form I has an X-ray powder diffraction pattern expressed at 2 theta angle having The following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2 ⁇ 0.2°.
  • the present disclosure relates to substantially pure Form I of the compound of formula (I), wherein, using Cu-K ⁇ radiation, the X-ray powder diffraction pattern of Form I in 2 ⁇ angles has the following Characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2 ⁇ 0.2°.
  • the present disclosure relates to a solvent-free and water-free crystalline form I of the compound of formula (I), wherein, using Cu-K ⁇ radiation, X-ray powder diffraction of the crystalline form I in 2 ⁇ angles
  • the spectrum has the following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2 ⁇ 0.2°.
  • Form I of the compound of formula (I) has substantially very uniform fine particles.
  • the diameter of the crystal form I of the compound represented by formula (I) is generally below 50 ⁇ m, which can increase the specific surface area of the drug, improve the dissolution rate, and facilitate the rapid absorption of the drug.
  • the crystal form I of the compound represented by formula (I) of the present disclosure has only a weight change of less than 0.03% in the range of 0-80% relative humidity, is not hygroscopic, and has better stability And workability, more conducive to storage.
  • the present disclosure relates to a method for preparing the crystal form I of the compound represented by formula (I), which comprises dissolving the compound represented by formula (I) in a halohydrin solvent, concentrating to obtain a solid, and dissolving the compound represented by formula (I) in a halogenated alcohol solvent.
  • the solid is dried to obtain the crystal form I, wherein, using Cu-K ⁇ radiation, the X-ray powder diffraction pattern of the crystal form I represented by the 2 ⁇ angle has the following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2 ⁇ 0.2°.
  • illustrative examples of halohydrin that can be used in the present disclosure include, but are not limited to, C 1-6 halohydrin.
  • C 1-6 halohydrins that can be used in the present disclosure include, but are not limited to, C 1-6 chlorohydrins, C 1-6 fluorohydrins, and any mixtures thereof.
  • C 1-6 fluoroalcohols that can be used in the present disclosure include, but are not limited to, trifluoroethanol.
  • the drying apparatus and method are not limited and may be fume hoods, forced air ovens, spray dryers, fluid bed drying and vacuum ovens.
  • drying can be performed under reduced or atmospheric pressure.
  • drying can be performed at a pressure of less than 0.09 MPa.
  • the drying temperature is about 10 to 50°C.
  • the drying temperature is about 40°C.
  • the drying time is about 0.5 to 5 hours.
  • the drying time is about 1 hour.
  • the present disclosure relates to a method for preparing a crystalline form I of a compound of formula (I), comprising in a solution of an acid salt of the compound of formula (I), using a base to free out formula (I)
  • the compound is obtained as a solid, and the solid is isolated, dried, and kept at 120 to 180° C. to obtain the crystal form I, wherein, using Cu-K ⁇ radiation, X-ray powder diffraction of the crystal form I in 2 ⁇ angles
  • the spectrum has the following characteristic peaks: 8.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.5 ⁇ 0.2° and 23.2 ⁇ 0.2°.
  • illustrative examples of acid salts of compounds of formula (I) that can be used in the present disclosure include, but are not limited to, hydrochloride, hydrobromide, sulfate, sulfonate, phosphoric acid salt and nitrate.
  • the acid salt of the compound of formula (I) that can be used in the present disclosure is a sulfate salt.
  • the base that can be used in the present disclosure is sodium hydroxide.
  • illustrative examples of solutions of acid salts of compounds of formula (I) that can be used in the present disclosure include, but are not limited to, aqueous solutions.
  • the drying apparatus and method are not limited and can be fume hoods, forced air ovens, spray dryers, fluid bed drying and vacuum ovens.
  • drying can be performed under reduced or atmospheric pressure.
  • drying can be performed at a pressure of less than 0.09 MPa.
  • the drying temperature is about 10 to 50°C.
  • the drying temperature is about 40°C.
  • the drying time is about 1 to 24 hours.
  • the drying time is about 16 hours.
  • the temperature maintained is about 140 to 150°C.
  • the temperature maintained is about 150°C;
  • the hold time is about 10 to 30 minutes.
  • the hold time is about 10 minutes.
  • the method for preparing the crystal form I of the compound represented by formula (I) of the present disclosure is simple and has few steps, which is more conducive to improving the efficiency of preparation and controlling parameters.
  • the present disclosure relates to the crystalline form II of the compound represented by formula (II),
  • the X-ray powder diffraction pattern of the crystal form II at 2 ⁇ angle has the following characteristic peaks: 3.3 ⁇ 0.2°, 5.7 ⁇ 0.2°, 8.6 ⁇ 0.2°, 11.8 ⁇ 0.2°, 14.2 ⁇ 0.2° and 18.2 ⁇ 0.2°.
  • the present disclosure relates to the crystalline form II of the compound represented by formula (II),
  • the X-ray powder diffraction pattern of the crystal form II at 2 ⁇ angle has the following characteristic peaks: about 3.3°, about 5.7°, about 8.6°, about 11.8°, about 14.2° and about 18.2° °.
  • the present disclosure relates to the crystalline form II of the compound represented by formula (II),
  • the X-ray powder diffraction pattern of the crystal form II at 2 ⁇ angle has the following characteristic peaks: 3.3 ⁇ 0.2°, 5.7 ⁇ 0.2°, 8.6 ⁇ 0.2°, 11.8 ⁇ 0.2°, 14.2 ⁇ 0.2°, 14.9 ⁇ 0.2°, 16.3 ⁇ 0.2°, 17.3 ⁇ 0.2°, 18.2 ⁇ 0.2°, 20.4 ⁇ 0.2°, 21.5 ⁇ 0.2° and 23.6 ⁇ 0.2°.
  • the present disclosure relates to the crystalline form II of the compound represented by formula (II),
  • the X-ray powder diffraction pattern of the crystal form II at 2 ⁇ angle has the following characteristic peaks: about 3.3°, about 5.7°, about 8.6°, about 11.8°, about 14.2°, about 14.9°, about 16.3°, about 17.3°, about 18.2°, about 20.4°, about 21.5°, and about 23.6°.
  • the present disclosure relates to the crystalline form II of the compound represented by formula (II),
  • the X-ray powder diffraction pattern of the crystal form II at 2 ⁇ angle has the following characteristic peaks: 3.3 ⁇ 0.2°, 5.7 ⁇ 0.2°, 6.5 ⁇ 0.2°, 8.6 ⁇ 0.2°, 11.3 ⁇ 0.2°, 11.8 ⁇ 0.2°, 14.2 ⁇ 0.2°, 14.9 ⁇ 0.2°, 16.3 ⁇ 0.2°, 17.3 ⁇ 0.2°, 18.2 ⁇ 0.2°, 19.9 ⁇ 0.2°, 20.4 ⁇ 0.2°, 21.5 ⁇ 0.2°, 23.6 ⁇ 0.2°, 24.8 ⁇ 0.2° and 26.0 ⁇ 0.2°.
  • the present disclosure relates to the crystalline form II of the compound represented by formula (II),
  • the X-ray powder diffraction pattern of the crystal form II at 2 ⁇ angle has the following characteristic peaks: about 3.3°, about 5.7°, about 6.5°, about 8.6°, about 11.3°, about 11.8°, about 14.2°, about 14.9°, about 16.3°, about 17.3°, about 18.2°, about 19.9°, about 20.4°, about 21.5°, about 23.6°, about 24.8°, and about 26.0°.
  • the present disclosure relates to the crystalline form II of the compound represented by formula (II),
  • the characteristic peaks and relative intensities of the X-ray powder diffraction pattern of the crystal form II represented by the angle of 2 ⁇ are about:
  • the present disclosure relates to the crystalline form II of the compound represented by formula (II),
  • the crystal form II basically has an X-ray powder diffraction pattern as shown in FIG. 5 .
  • Form II of the compound of formula (II) has an X-ray powder diffraction pattern that exhibits at least one characteristic peak substantially as shown in the X-ray powder diffraction pattern of FIG. 5 .
  • Form II of the compound of formula (II) has an X-ray powder diffraction pattern exhibiting at least two characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 5 .
  • Form II of the compound of formula (II) has an X-ray powder diffraction pattern exhibiting at least three characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 5 .
  • Form II of the compound of formula (II) has an X-ray powder diffraction pattern exhibiting at least four characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 5 .
  • Form II of the compound of formula (II) has an X-ray powder diffraction pattern exhibiting at least five characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 5 .
  • Form II of the compound of formula (II) has an X-ray powder diffraction pattern exhibiting at least six characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 5 .
  • Form II of the compound of formula (II) has an X-ray powder diffraction pattern exhibiting at least seven characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 5 .
  • Form II of the compound of formula (II) has an X-ray powder diffraction pattern exhibiting at least eight characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 5 .
  • Form II of the compound of formula (II) has an X-ray powder diffraction pattern exhibiting at least nine characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 5 .
  • Form II of the compound of formula (II) has an X-ray powder diffraction pattern exhibiting at least ten peaks substantially characteristic of the X-ray powder diffraction pattern as shown in FIG. 5 .
  • Form II of the compound of formula (II) has an X-ray powder diffraction pattern that exhibits at least eleven characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 5 . .
  • Form II of the compound of formula (II) has an X-ray powder diffraction pattern exhibiting at least twelve characteristic peaks substantially as shown in the X-ray powder diffraction pattern of FIG. 5 .
  • Form II of the compound of formula (II) has an X-ray powder diffraction pattern exhibiting at least thirteen peaks substantially characteristic of the X-ray powder diffraction pattern as shown in FIG. 5 .
  • Form II of the compound of formula (II) has an X-ray powder diffraction pattern exhibiting at least fourteen peaks substantially characteristic of the X-ray powder diffraction pattern as shown in FIG. 5 .
  • Form II of the compound of formula (II) has an X-ray powder diffraction pattern exhibiting at least fifteen peaks characteristic of the X-ray powder diffraction pattern substantially as shown in FIG. 5 . .
  • Form II of the compound of formula (II) has an X-ray powder diffraction pattern exhibiting at least sixteen peaks characteristic of the X-ray powder diffraction pattern substantially as shown in FIG. 5 . .
  • Form II of the compound of formula (II) has an X-ray powder diffraction pattern exhibiting at least seventeen peaks characteristic of the X-ray powder diffraction pattern substantially as shown in FIG. 5 . .
  • Form II of the compound of formula (II) has substantially the DSC curve shown in FIG. 6 when thermally analyzed using differential scanning calorimetry (DSC).
  • the crystalline form II of the compound represented by formula (II) has substantially as shown in FIG. 6 DSC curve shown.
  • Form II of the compound of formula (II) is between 36°C and 110°C and between 110°C and 132°C when thermally analyzed using differential scanning calorimetry (DSC) There is one desolvation peak, respectively.
  • the crystalline form II of the compound of formula (II) is between 36°C and 110°C
  • Form II of the compound of formula (II) has substantially the TGA curve shown in FIG. 7 when thermally analyzed using thermogravimetric analysis (TGA).
  • thermogravimetric analysis when thermal analysis is performed using thermogravimetric analysis (TGA), at a heating rate of 10° C./min, the crystalline form II of the compound represented by formula (II) has substantially as shown in FIG. 7 . TGA curve.
  • thermogravimetric analysis TGA
  • thermogravimetric analysis TGA
  • the crystal form II of the compound represented by formula (II) has a step weight loss, and the step weight loss is about 7.7%, indicating that it is dihydrate.
  • the present disclosure relates to substantially pure crystalline Form II of the compound of formula (II), wherein, using Cu-K ⁇ radiation, the crystalline Form II has an X-ray powder diffraction pattern at 2 theta having the following Characteristic peaks: 3.3 ⁇ 0.2°, 5.7 ⁇ 0.2°, 8.6 ⁇ 0.2°, 11.8 ⁇ 0.2°, 14.2 ⁇ 0.2° and 18.2 ⁇ 0.2°.
  • the crystal form II of the compound represented by formula (II) is a block-shaped granular crystal with better morphology and better fluidity, which can reduce the filtration time of the drug substance and the sieving of the preparation. time, which is conducive to accurate metering and improved efficiency in formulation production.
  • the crystalline form II of the compound represented by formula (II) is a block-like granular crystal with better morphology and better formulation processability, which can be used for direct powder compression, avoiding wet
  • the influence of granulation solvent on API is beneficial to control the quality of preparation and improve batch stability.
  • the crystal form II of the compound represented by formula (II) has excellent water stability, is more suitable for wet granulation, has better crystal form stability in water-containing crystallization processes, and has Better storage stability.
  • the present disclosure relates to a method for preparing the crystal form II of the compound represented by formula (II), which comprises mixing a solution of the compound represented by formula (I) with an antisolvent to obtain a solid, and separating and drying the solid , to obtain the crystal form II, wherein, using Cu-K ⁇ radiation, the X-ray powder diffraction pattern of the crystal form II at 2 ⁇ angle has the following characteristic peaks: 3.3 ⁇ 0.2°, 5.7 ⁇ 0.2°, 8.6 ⁇ 0.2 °, 11.8 ⁇ 0.2°, 14.2 ⁇ 0.2° and 18.2 ⁇ 0.2°.
  • illustrative examples of solvents that can be used to dissolve the compound represented by formula (I) include, but are not limited to, mixed solvents of organic solvents and water.
  • the volume ratio of organic solvent to water in the solvent in which the compound of formula (I) is dissolved is about 1:0.1 to 0.5.
  • the volume ratio of organic solvent to water in the solvent in which the compound of formula (I) is dissolved is about 1:0.2 to 0.4.
  • antisolvents that can be used in the present disclosure include, but are not limited to, water.
  • the volume ratio of organic solvent to antisolvent in the solvent in which the compound of formula (I) is dissolved is about 1:1 to 10.
  • the volume ratio of organic solvent to antisolvent in the solvent in which the compound of formula (I) is dissolved is about 1:3 to 5.
  • the mass-to-volume ratio of the compound of formula (I) to the solvent in which it is dissolved is about 10 to 100 mg/mL.
  • the mass-to-volume ratio of the compound of formula (I) to the solvent in which it is dissolved is about 20 to 50 mg/mL.
  • the drying apparatus and method are not limited and may be fume hoods, forced air ovens, spray dryers, fluid bed drying and vacuum ovens.
  • drying can be performed under reduced or atmospheric pressure.
  • drying can be performed at a pressure of less than 0.09 MPa.
  • the drying temperature is about 10 to 50°C.
  • the drying temperature is about 40°C.
  • the drying time is about 1 to 24 hours.
  • the drying time is about 16 hours.
  • the present disclosure relates to a method for preparing the crystal form II of the compound represented by the formula (II), which comprises dissolving the compound represented by the formula (I) in a mixed solvent of an organic solvent and water to form a solution, and cooling the compound The solution obtains a solid, and the solid is separated and dried to obtain the crystal form II, wherein, using Cu-K ⁇ radiation, the X-ray powder diffraction pattern of the crystal form II at 2 ⁇ angle has the following characteristic peaks: 3.3 ⁇ 0.2°, 5.7 ⁇ 0.2°, 8.6 ⁇ 0.2°, 11.8 ⁇ 0.2°, 14.2 ⁇ 0.2° and 18.2 ⁇ 0.2°.
  • the volume ratio of organic solvent to water in the mixed solvent is about 1:0.1 to 0.5.
  • the volume ratio of organic solvent to water in the mixed solvent is about 1:0.2 to 0.4.
  • the mass volume ratio of the compound represented by formula (I) to the mixed solvent is about 10 to 100 mg/mL.
  • the mass volume ratio of the compound represented by formula (I) to the mixed solvent is about 20 to 50 mg/mL.
  • the temperature at which the solution is formed is about 60 to 80°C.
  • the temperature at which the solution is formed is about 65 to 75°C.
  • the cooling temperature is about -5 to 10°C.
  • the temperature of cooling is about 0 to 4°C.
  • the drying apparatus and method are not limited and may be fume hoods, forced air ovens, spray dryers, fluid bed drying and vacuum ovens.
  • drying can be performed under reduced or atmospheric pressure.
  • drying can be performed at a pressure of less than 0.09 MPa.
  • the drying temperature is about 10 to 50°C.
  • the drying temperature is about 40°C.
  • the drying time is about 1 to 24 hours.
  • the drying time is about 16 hours.
  • the present disclosure relates to a method for preparing the crystal form II of the compound represented by formula (II), which comprises stirring an aqueous suspension of the compound represented by formula (I), filtering and drying to obtain the crystal form II,
  • a method for preparing the crystal form II of the compound represented by formula (II) which comprises stirring an aqueous suspension of the compound represented by formula (I), filtering and drying to obtain the crystal form II,
  • the X-ray powder diffraction pattern of the crystal form II at 2 ⁇ angle has the following characteristic peaks: 3.3 ⁇ 0.2°, 5.7 ⁇ 0.2°, 8.6 ⁇ 0.2°, 11.8 ⁇ 0.2°, 14.2 ⁇ 0.2° and 18.2 ⁇ 0.2°.
  • the temperature of agitation is about 10 to 45°C.
  • the stirring temperature is about room temperature.
  • the drying apparatus and method are not limited and may be fume hoods, forced air ovens, spray dryers, fluid bed drying and vacuum ovens.
  • drying can be performed under reduced or atmospheric pressure.
  • drying can be performed at a pressure of less than 0.09 MPa.
  • the method for preparing the crystal form II of the compound represented by formula (II) disclosed in the present disclosure is simple, requires small types and amounts of organic solvents, is more conducive to green pharmacy, and has simpler steps.
  • Form I of the compound of formula (I) has substantially very uniform fine particles.
  • the diameter of the crystal form I of the compound represented by formula (I) is generally below 50 ⁇ m, which can increase the specific surface area of the drug, improve the dissolution rate, and facilitate the rapid absorption of the drug.
  • Form I of the compound of formula (I) of the present disclosure has only less than 0.03% weight change in the 0-80% relative humidity range.
  • formula (II) The crystal form II of the compound shown is a block-like granular crystal with better morphology and better fluidity, which can reduce the filtration time of the API and the sieving time of the preparation, which is beneficial to the accurate measurement and production of the preparation. Improve efficiency.
  • the crystalline form II of the compound represented by formula (II) is a block-like granular crystal with better morphology and better formulation processability, which can be used for direct powder compression, avoiding wet
  • the influence of granulation solvent on API is beneficial to control the quality of preparation and improve batch stability.
  • the crystal form II of the compound represented by formula (II) has excellent water stability, is more suitable for wet granulation, has better crystal form stability in water-containing crystallization processes, and has Better storage stability.
  • the present disclosure relates to a pharmaceutical composition
  • a pharmaceutical composition comprising crystal form I of the compound represented by formula (I) of the present disclosure, crystal form II of the compound represented by formula (II) of the present disclosure, or formula of the present disclosure Any mixture of the crystalline form I of the compound represented by (I) and the crystalline form II of the compound represented by the formula (II) of the present disclosure, and a pharmaceutically acceptable carrier, diluent or excipient.
  • the crystalline form I of the compound of formula (I) of the present disclosure is used for the treatment or prevention of tyrosine kinase 2-related diseases or disease states.
  • the routes of administration include, but are not limited to, oral, lingual Subcutaneous, intravenous, intramuscular, nasal, topical and rectal routes of administration.
  • oral formulations that can be used in the present disclosure include, but are not limited to, tablets, capsules, powders, granules, solutions, and suspensions.
  • Examples of pharmaceutically acceptable carriers that can be used in the pharmaceutical compositions of the present disclosure include, but are not limited to, any adjuvant, carrier, excipient, adjuvant that has been approved by the U.S. Food and Drug Administration for use in humans or animals.
  • Various forms of carriers without adverse effects to make up the pharmaceutical composition are well known in the pharmaceutical arts.
  • the pharmaceutical compositions of the present disclosure can be administered by any method that achieves their intended purpose.
  • administration can be by oral, parenteral, topical, enteral, intravenous, intramuscular, inhalation, nasal, intraarticular, intraspinal, transtracheal, ocular, subcutaneous, intraperitoneal, transdermal, or buccal routes. conduct.
  • the route of administration can be parenteral, oral, and intrarectal.
  • the dose administered will depend on the age, health, and weight of the recipient, and, if any, concomitant therapy, the type of concurrent therapy, the frequency of the therapy, and the nature of the desired effect.
  • Suitable dosage forms include, but are not limited to, capsules, tablets, pellets, dragees, semisolids, powders, granules, suppositories, ointments, creams, lotions, inhalants, injections, ointments , gels, tapes, eye drops, solutions, syrups, aerosols, suspensions, emulsions, which can be prepared according to methods known in the art.
  • Particularly suitable for oral administration are ordinary tablets (plain tablets), sugar-coated tablets, film-coated tablets, pills, capsules, powders, granules, syrups, juices or drops, and those suitable for rectal administration are suppositories
  • suitable for Parenteral administration is in the form of solutions, also oil-based or aqueous solutions, in addition to suspensions, emulsions or implants, and suitable for topical use as ointments, creams, creams, suppositories or powders.
  • the products of the present disclosure can also be lyophilized and the resulting lyophilisates used, for example, in the preparation of injectables.
  • the products in the present disclosure can also be made into solid dispersions for oral preparations, such as tablets or capsules, and the methods of preparing solid dispersions can adopt conventional methods, such as spray drying/hot melt extrusion/lyophilization, etc.,
  • the compounds of the present application can be uniformly dispersed in polymers, including but not limited to celluloses, ?
  • the cellulose can be: hydroxypropyl methyl cellulose acetate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose acetate and one or more of hydroxyethyl ethyl cellulose acetic acid and combinations thereof
  • the non-cellulose can be: one or both of polyacrylate, acrylate and methacrylate copolymer the above and combinations thereof.
  • the formulations given may be sterilized and/or contain adjuvants such as wetting agents, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for varying the osmotic pressure, buffer substances, Dyes, flavors and/or numerous additional active ingredients, such as one or more vitamins.
  • adjuvants such as wetting agents, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for varying the osmotic pressure, buffer substances, Dyes, flavors and/or numerous additional active ingredients, such as one or more vitamins.
  • Preservatives can be provided in the pharmaceutical composition.
  • sodium benzoate, ascorbic acid, and esters of p-hydroxybenzoic acid may be added as preservatives.
  • antioxidants and suspending agents can be used.
  • alcohols, esters, sulfated aliphatic alcohols, etc. can be used as surfactants; sucrose, glucose, lactose, starch, crystalline cellulose, mannitol, light anhydrous silicates, magnesium aluminate , magnesium aluminate methyl silicate, synthetic aluminum silicate, calcium carbonate, calcium bicarbonate, calcium hydrogen phosphate, calcium hydroxymethyl cellulose, etc. can be used as excipients; magnesium stearate, talc, hardened oil, etc. can be used as excipients.
  • a lubricating agent Used as a lubricating agent; coconut oil, olive oil, sesame oil, peanut oil, soybean oil can be used as a suspending agent or lubricant; cellulose acetate as a derivative of sugars such as cellulose or sugar, or as a derivative of polyethylene Polymethyl acetate-methacrylate copolymers of phthalates can be used as suspending agents; and plasticizers such as phthalates can be used as suspending agents.
  • Suitable routes of administration may include, for example, oral (immediate, sustained or controlled release), rectal, transmembrane, parenteral, transdermal, topical or enteral; parenteral External delivery includes intramuscular, subcutaneous, intravenous, intramedullary, and intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injection.
  • the compounds can also be extended at predetermined rates and/or in sustained or controlled release dosage forms including depot injections, osmotic pumps, pills, transdermal (including electromigration) patches, and the like. Timed, pulsed administration.
  • compositions of the present disclosure can be produced by known methods, eg, by conventional mixing, dissolving, granulating, dragee-making, milling, emulsifying, encapsulating, entrapping, or tableting procedures.
  • compositions for use may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into Pharmaceutically acceptable preparations.
  • physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into Pharmaceutically acceptable preparations.
  • Appropriate formulations depend on the route of administration chosen. Any of the well known techniques, carriers and excipients may be used as appropriate and understood in the art.
  • Injectables can be prepared in conventional forms: as solutions or suspensions, solid dosage forms suitable for solution or suspension prior to injection, or as emulsions.
  • Suitable excipients are, for example, water, saline, dextrose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine hydrochloride and the like.
  • the pharmaceutical composition for injection may contain a small amount of non-toxic adjuvants such as wetting agents, pH buffering agents and the like.
  • Physiologically suitable buffers include, but are not limited to, Hank's solution, Ringer's solution, or physiological saline buffer. If desired, absorption enhancing formulations (eg, liposomes) can be used.
  • the compounds can be readily formulated by combining the active compounds with pharmaceutically acceptable carriers well known in the art.
  • Such carriers enable the compounds of the invention to be formulated as tablets, pills, lozenges, capsules, liquids, gels, syrups, slurries, suspensions, solutions, powders and the like for oral ingestion by a patient to be treated.
  • Pharmaceutical preparations for oral administration can be obtained by mixing the active compound with a solid excipient, optionally grinding the resulting mixture and processing the mixture of granules, if necessary after adding suitable auxiliaries, to obtain tablets or Lozenge core.
  • Suitable excipients are especially fillers such as sugars, including lactose, sucrose, mannitol or sorbitol; cellulosic preparations, such as corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl methacrylate cellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone (PVP).
  • Disintegrants such as cross-linked polyvinylpyrrolidone, agar or alginic acid or alginates such as sodium alginate can be added if desired. Lozenge cores are suitably coated.
  • concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol and/or titanium dioxide, shellac lacquer solutions and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol and/or titanium dioxide, shellac solutions, and suitable organic solvent or solvent mixture.
  • compositions that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin, such as glycerol or sorbitol, and a plasticizer.
  • the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. Additionally, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.
  • the pharmaceutical compositions of the present disclosure may comprise 0.1% to 95% of the crystalline form I of the compound of formula (I) of the present disclosure.
  • compositions of the present disclosure may comprise 1% to 70% of the crystalline form I of the compound of formula (I) of the present disclosure.
  • composition or formulation to be administered will contain an amount of Form I of a compound of formula (I) of the present disclosure effective to treat the disease/condition of the subject being treated.
  • the pharmaceutical composition of the present disclosure may comprise 0.1%-95% of the crystalline form II of the compound of formula (II) of the present disclosure.
  • compositions of the present disclosure may comprise 1% to 70% of the crystalline form II of the compound of formula (II) of the present disclosure.
  • composition or formulation to be administered will contain an amount of Form II of a compound of formula (II) of the present disclosure effective to treat the disease/condition of the subject being treated.
  • the present disclosure relates to a method of treating or preventing a disease or disease state associated with tyrosine kinase 2, comprising administering to an individual in need of the method a therapeutically or prophylactically effective amount of formula (I) of the present disclosure
  • a therapeutically or prophylactically effective amount of formula (I) of the present disclosure comprising administering to an individual in need of the method a therapeutically or prophylactically effective amount of formula (I) of the present disclosure
  • the crystal form I of the compound represented by the formula (II) of the present disclosure or the crystal form I of the compound represented by the formula (I) of the present disclosure and the compound represented by the formula (II) of the present disclosure Any mixture of the crystalline Form II, or a therapeutically effective amount of the pharmaceutical composition of the present disclosure.
  • the individual is a mammal.
  • the individual is a human.
  • illustrative examples of diseases or disease states that can be used in the present disclosure include, but are not limited to, diseases or disease states associated with TYK2.
  • illustrative examples of diseases or disease states that can be used in the present disclosure include, but are not limited to, autoimmune and auto-inflammatory related diseases or disease states.
  • autoimmune and autoinflammatory related diseases or disease states that can be used in the present disclosure include, but are not limited to, psoriasis, plaque psoriasis, psoriatic joints inflammation, lupus, lupus nephritis, Sjogren's syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and ankylosing spondylitis.
  • a method of treating or preventing a disease or disease state associated with tyrosine kinase 2 comprises administering to an individual in need of the method 1 mg-10 g of a compound of formula (I) of the present disclosure Crystal form I, crystal form II of the compound represented by formula (II), or a mixture thereof.
  • a method of treating or preventing a disease or disease state associated with tyrosine kinase 2 comprises administering to an individual in need of the method 10 mg-3000 mg of a compound of formula (I) of the present disclosure Crystal form I, crystal form II of the compound represented by formula (II), or a mixture thereof.
  • a method of treating or preventing a disease or disease state associated with tyrosine kinase 2 comprises administering to an individual in need of the method 1 mg-200 mg of a compound of formula (I) of the present disclosure Crystal form I, crystal form II of the compound represented by formula (II), or a mixture thereof.
  • a method of treating or preventing a disease or disease state associated with tyrosine kinase 2 comprises administering to an individual in need of the method about 1-500 mg, specifically 1 mg, 2 mg, 2.5 mg, 3 mg , 3.5mg, 4mg, 4.5mg, 5mg, 6mg, 7mg, 8mg, 9mg, 10mg, 12mg, 15mg, 18mg, 20mg, 24mg, 25mg, 30mg, 35mg, 36mg, 40mg, 45mg, 50mg, 60mg, 70mg, 90mg , 100 mg, 120 mg, 150 mg, or 200 mg of the crystalline form I of the compound represented by formula (I) of the present disclosure, the crystalline form II of the compound represented by formula (II), or a mixture thereof.
  • the number of administrations can be once a day, every other day, twice a day, three times a day, and the like.
  • the method of treating or preventing a tyrosine kinase 2-related disease or condition further comprises simultaneously or sequentially administering at least one disease or condition capable of treating or preventing a tyrosine kinase 2-related disease or condition of other active ingredients.
  • illustrative examples of other active ingredients include, but are not limited to, corticosteroids, rolipram, calphostin, cytokine-suppressing anti-inflammatory drugs (CSAID), interleukin-10, glucocorticoids, salicylates, nitric oxide and other immunosuppressants; nuclear translocation inhibitors such as deoxyspergualin (DSG); Inflammatory drugs (NSAIDs), such as ibuprofen, celecoxib, and rofecoxib; steroids, such as prednisone or dexamethasone; antiviral agents , eg, abacavir; antiproliferative agents, eg, methotrexate, leflunomide, FK506 (tacrolimus); antimalarial agents, eg, hydroxychloroquine; Cytotoxic drugs such as azathiprine and cyclophosphamide; TNF-
  • At least one crystalline form I of the compound represented by formula (I), crystalline form II of the compound represented by formula (II), or crystalline form I and formula (II) of the compound represented by formula (I) of the present disclosure can be ) of the compound represented by the crystal form II of the mixture, or comprising at least one of the crystal form I of the compound represented by the formula (I), the crystal form II of the compound represented by the formula (II) or the formula (I) of the present disclosure
  • the pharmaceutical composition of a mixture of Form I of the compound shown and Form II of the compound of Formula (II) is carried out by any suitable method for systemic and/or local delivery of Form I of the compound of the present disclosure. method to administer the drug to the patient.
  • Non-limiting examples of methods of administration include (a) administration by the oral route, including administration in capsules, tablets, granules, sprays, syrups, or other such forms; (b) administration by non- Oral route of administration, such as rectal, vaginal, intraurethral, intraocular, intranasal, or intrathecal, including in aqueous suspensions, oily formulations, etc., or in drops, sprays, suppositories, ointments, ointments, etc.
  • transdermal administration includes administration in the form of ointments, creams, gels, aerosols, suspensions, creams, creams or other such forms.
  • compositions suitable for administration include those in which the active ingredient is contained in an amount effective to achieve its intended effect.
  • the dosage required for a therapeutically effective amount of a pharmaceutical composition described in this disclosure will depend on the route of administration, the type of animal being treated, including humans, and the physical characteristics of the particular animal under consideration. Dosage can be adjusted to achieve the desired effect, but will depend on factors such as body weight, diet, concomitant medication and other factors recognized by those skilled in the medical arts. More specifically, a therapeutically effective amount refers to an amount of a crystalline form of the compound effective to prevent, reduce or ameliorate the symptoms of a disease, or prolong the lifespan of an individual receiving treatment. A therapeutically effective amount is well within the practical ability of those skilled in the art, particularly in light of the detailed disclosure provided in this disclosure.
  • the dosage for in vivo administration and the particular mode of administration will vary depending on the age, weight and species of mammal being treated, the crystal form of the particular compound used and the specific uses of the crystalline forms of these compounds.
  • Those skilled in the art can use conventional pharmacological methods to determine effective dosage levels, ie, the dosage levels necessary to determine the desired effect.
  • human clinical use of the product is initiated at lower dose levels, with increasing dose levels until the desired effect is achieved.
  • acceptable in vitro studies can be used to establish effective doses and routes of administration for the compositions identified by this method.
  • dosages can range from about 10 ⁇ g/kg body weight to 1000 mg/kg body weight, and in certain embodiments from about 100 ⁇ g/kg body weight to 300 mg/kg body weight.
  • the dose may be based on and calculated from the patient's body surface area.
  • the dose of the composition administered to a patient may range from about 0.5 mg/kg to 1000 mg/kg of the patient's body weight.
  • the doses may be administered individually or in two or more doses over the course of one or several days, as desired by the patient.
  • human doses for a crystalline form of the compound are established for at least some conditions, the present disclosure will use those same doses, or a dose ranging from about 0.1% to 500% of the established human doses, in certain implementations Dosages in the regimen ranged from 25% to 250% of the established human dose.
  • suitable human doses can be derived from the median effective dose or the median infectious dose, or other suitable values from in vitro or in vivo studies Inferred, as quantified in toxicity studies and efficacy studies in animals.
  • the attending physician will know how and when to terminate, interrupt or adjust dosing due to toxicity and organ dysfunction. Conversely, if the clinical response is insufficient (excluding toxicity), the attending physician will also know to adjust treatment to higher levels.
  • the size of the dose administered in the treatment of the condition of interest will vary with the severity of the disease state being treated and the route of administration. The severity of the disease state can be assessed, for example, in part by standard prognostic assessment methods.
  • the dose and possible dose frequency will also vary depending on the age, weight, and response of the individual patient. A protocol comparable to the protocol discussed above can be used in veterinary medicine.
  • the daily dosage regimen for an adult patient is, for example, an oral dose of 0.1 mg to 2000 mg of each active ingredient, in certain embodiments 1 mg to 2000 mg of each active ingredient, eg, 5 mg to 1500 mg of each active ingredient.
  • the intravenous, subcutaneous or intramuscular dose of each active ingredient used is 0.01 mg to 1000 mg, in certain embodiments 0.1 mg to 1000 mg, such as 1 mg to 800 mg.
  • the dosage can be calculated as the free base.
  • the composition is administered 1 to 4 times daily.
  • compositions described in the present disclosure may be administered by continuous intravenous infusion, in certain embodiments at doses of up to 2000 mg per day of each active ingredient.
  • doses of up to 2000 mg per day of each active ingredient.
  • the compound is administered over a period of continuous treatment, eg, one week or several weeks, or months or years.
  • Dosage and dosing intervals can be adjusted individually to provide plasma levels of the active moiety sufficient to maintain the adjusted effect or minimum effective concentration (MEC).
  • MEC adjusted for each compound, but MEC can be assessed from in vitro data.
  • the dose required to achieve the MEC will depend on individual characteristics and route of administration. However, plasma concentrations can be determined using HPLC (High Performance Liquid Chromatography) assays or bioassays.
  • Dosing intervals can also be determined using the MEC value. Treatment should be used that maintains plasma levels above the MEC 10-90% of the time, in certain embodiments 30-90% of the time, and in certain embodiments 50-90% of the time The regimen administers the composition.
  • the effective local concentration of the drug is independent of the plasma concentration.
  • the amount of the composition to be administered will depend on the individual being treated, on the weight of the individual, the severity of the distress, the mode of administration, and the judgment of the prescribing physician.
  • the efficacy and toxicity of the compounds described in this disclosure can be assessed using known methods.
  • the toxicology of a particular compound, or a subset of the compound that shares certain chemical moieties can be established by assaying the toxicity of a cell line in vitro, such as a mammalian cell line and, in certain embodiments, a human cell line. The results of such studies generally predict toxicity in animals such as mammals, or more specifically, in humans.
  • the toxicity of a particular compound in animal models such as mice, rats, rabbits or monkeys can be determined using known methods.
  • the potency of a particular compound can be determined using several recognized methods, such as in vitro methods, animal models or human clinical trials.
  • compositions can, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
  • the package may, for example, comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may carry instructions for administration.
  • the packaging or dispensing device may also carry a notice associated with the container, the notice being prescribed by a governmental agency regulating the manufacture, use or sale of a drug, the notice reflecting that the drug form has been approved by the agency Approved for human or veterinary administration.
  • Such notices may, for example, be labels approved by the State Food and Drug Administration or the U.S. Food and Drug Administration for prescription drugs, or approved product inserts.
  • Compositions comprising a compound of the present disclosure, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof can also be formulated in a suitable container, placed in a compatible pharmaceutical carrier, and labeled for use. treatment for the specified disease state.
  • X-ray powder diffraction (XRPD): The instrument is a Bruker D8 Advance diffractometer. Samples were tested at room temperature. The detection conditions are as follows, angle range: 3 to 40° 2 ⁇ , step size: 0.02° 2 ⁇ , speed: 0.2 sec/step.
  • Polarized light microscopy (PLM) spectra were obtained from XP-500E polarized light microscope. Take a small amount of powder sample and place it on a glass slide, add a small amount of mineral oil dropwise to disperse the sample, cover it with a cover glass, place it on the stage for observation and take pictures.
  • PLM Polarized light microscopy
  • DSC Differential Scanning Calorimetry
  • Thermogravimetric analysis (TGA) data were obtained from TA Instruments Q500 TGA.
  • the detection method is as follows: take 5 to 15 mg of the sample and place it in a platinum crucible, adopt the method of segmented high-resolution detection, and raise the sample from room temperature to 40 mL/min under the protection of dry N2 at a heating rate of 10 °C/min. 300°C.
  • Dynamic moisture sorption analysis (DVS) data and isothermal sorption analysis data were obtained from TA Instruments Q5000 TGA.
  • the detection method is as follows: take a sample of 1 to 10 mg and place it in a platinum crucible, and detect the weight change during the change of relative humidity from 0% to 80% to 0%.
  • the embodiments of the present disclosure are all operated at room temperature.
  • Example 2 of patent application CN110914260A the crystal form A of Deucravicitinib (that is, the compound represented by formula (I)) is prepared, and the specific steps are as follows:
  • a solution was prepared by mixing 2 g of the compound of formula (I) into 143 mL of tetrahydrofuran and 7 mL of water at room temperature (25°C) until the compound of formula (I) was completely dissolved.
  • the solution was polished filter at room temperature and then dried overnight using a Speed vac.
  • the resulting solid was suspended in 12 mL of ethyl acetate at 60°C, and the resulting slurry was aged at 60°C overnight.
  • the slurry was filtered and the wet cake was washed with 5 mL of ethyl acetate.
  • the wet cake was dried in a vacuum oven at a temperature in the range of 50 to 60° C. to obtain 1.4 g of Form A of the compound represented by formula (I).
  • the XRPD pattern of the crystal form I of the compound represented by formula (I) is shown in FIG. 1 .
  • the DSC curve of the crystal form I of the compound represented by formula (I) is shown in FIG. 2 .
  • the TGA curve of the crystal form I of the compound represented by formula (I) is shown in FIG. 3 .
  • the DVS curve of the crystal form I of the compound represented by formula (I) is shown in FIG. 4 .
  • the product prepared in Example 2 has the same or similar XRPD spectrum, DSC curve, TGA curve and DVS curve as the product prepared in Example 1, which shows that the product prepared in Example 2 and the product prepared in Example 1 are have the same crystal form.
  • the XRPD pattern of the crystal form II of the compound represented by formula (II) is shown in FIG. 5 .
  • the DSC curve of the crystal form II of the compound represented by formula (II) is shown in FIG. 6 .
  • the TGA curve of the crystal form II of the compound represented by formula (II) is shown in FIG. 7 .
  • the products prepared in Examples 4 to 8 have the same or similar XRPD spectra, DSC curves and TGA curves as the products prepared in Example 3, which indicates that the products prepared in Examples 4 to 8 are the same as those prepared in Example 3. have the same crystal form.
  • the preparation contains the crystal form I prepared in Example 1, then shake at 25°C ⁇ 2°C, and take samples at 60 min to check the solubility of the sample by HPLC (see Table 1 for the HPLC method).
  • Example 1 Take the crystal form I prepared in Example 1, mix the crystal form I, anhydrous lactose, microcrystalline cellulose and hydroxypropyl cellulose K4M according to the recipe quantity in Table 5, and screen the mixed combination.
  • the screened mixture is mixed with magnesium stearate, the screened mixture is mixed with magnesium stearate, dry granulated (slug/roller process), and then ground. It is further mixed with magnesium stearate to prepare tablets, each tablet weighing about 300 mg.
  • relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply that any such relationship exists between these entities or operations. an actual relationship or sequence.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sont divulguées une forme cristalline I d'un composé tel que représenté dans la formule (I) et une forme cristalline II d'un composé tel que représenté dans la formule (II), le composé tel que représenté dans la formule (I) et le composé tel que représenté dans la formule (II) étant tels que décrits dans la présente divulgation.
PCT/CN2021/125043 2020-10-20 2021-10-20 Forme cristalline d'un dérivé pyridazinique WO2022083649A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202180069237.3A CN116615200A (zh) 2020-10-20 2021-10-20 哒嗪衍生物的晶型

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011114210.5 2020-10-20
CN202011114210 2020-10-20

Publications (1)

Publication Number Publication Date
WO2022083649A1 true WO2022083649A1 (fr) 2022-04-28

Family

ID=81291571

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/125043 WO2022083649A1 (fr) 2020-10-20 2021-10-20 Forme cristalline d'un dérivé pyridazinique

Country Status (2)

Country Link
CN (1) CN116615200A (fr)
WO (1) WO2022083649A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023181075A1 (fr) * 2022-03-24 2023-09-28 Dr. Reddy's Laboratories Limited Dispersions solides amorphes de deucravacitinib et leurs procédés de préparation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884454A (zh) * 2012-11-08 2015-09-02 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα应答调节剂的酰胺取代的杂环化合物
WO2018183656A1 (fr) * 2017-03-30 2018-10-04 Bristol-Myers Squibb Company Forme cristalline du 6-(cyclopropanecarboxamido)-4-((2-méthoxy-3-(1-méthyl-1h-1,2,4-triazol-3-yl)phényl)amino)-n-(méthyl-d3)pyridazine-3-carboxamide
WO2019232138A1 (fr) * 2018-05-31 2019-12-05 Bristol-Myers Squibb Company Forme cristalline de 6-(cyclopropanecarboxamido)-4-((2-méthoxy-3-(1-méthyl-1h-1,2,4-triazol-3-yl)phényl)amino)-n-(méthyl-d3) pyridazine-3-carboxamide
WO2021129467A1 (fr) * 2019-12-27 2021-07-01 苏州科睿思制药有限公司 Forme cristalline bms-986165, son procédé de préparation et son utilisation
WO2021143498A1 (fr) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 Forme cristalline de deucravacitinib, son procédé de préparation et son utilisation
WO2021143430A1 (fr) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 Forme cristalline de chlorhydrate de bms-986165, son procédé de préparation et son utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3873900A1 (fr) * 2018-10-30 2021-09-08 Gilead Sciences, Inc. Dérivés d'imidazopyridine utilisés en tant qu'inhibiteurs de l'intégrine alpha4bêta7

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884454A (zh) * 2012-11-08 2015-09-02 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα应答调节剂的酰胺取代的杂环化合物
WO2018183656A1 (fr) * 2017-03-30 2018-10-04 Bristol-Myers Squibb Company Forme cristalline du 6-(cyclopropanecarboxamido)-4-((2-méthoxy-3-(1-méthyl-1h-1,2,4-triazol-3-yl)phényl)amino)-n-(méthyl-d3)pyridazine-3-carboxamide
CN110475774A (zh) * 2017-03-30 2019-11-19 百时美施贵宝公司 用于制备6-(环丙烷酰氨基)-4-((2-甲氧基-3-(1-甲基-1h-1,2,4-三唑-3-基)苯基)氨基)-n-(甲基-d3)哒嗪-3-甲酰胺的方法
WO2019232138A1 (fr) * 2018-05-31 2019-12-05 Bristol-Myers Squibb Company Forme cristalline de 6-(cyclopropanecarboxamido)-4-((2-méthoxy-3-(1-méthyl-1h-1,2,4-triazol-3-yl)phényl)amino)-n-(méthyl-d3) pyridazine-3-carboxamide
WO2021129467A1 (fr) * 2019-12-27 2021-07-01 苏州科睿思制药有限公司 Forme cristalline bms-986165, son procédé de préparation et son utilisation
WO2021143498A1 (fr) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 Forme cristalline de deucravacitinib, son procédé de préparation et son utilisation
WO2021143430A1 (fr) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 Forme cristalline de chlorhydrate de bms-986165, son procédé de préparation et son utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAMES R. BURKE, LIHONG CHENG, KATHLEEN M. GILLOOLY, JOANN STRNAD, ADRIANA ZUPA-FERNANDEZ, IAN M. CATLETT, YIFAN ZHANG, ELIZABETH M: "Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain", SCIENCE TRANSLATIONAL MEDICINE, vol. 11, no. 502, 24 July 2019 (2019-07-24), pages eaaw1736, XP055682305, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aaw1736 *
STEPHEN T. WROBLESKI, RYAN MOSLIN, SHUQUN LIN, YANLEI ZHANG, STEVEN SPERGEL, JAMES KEMPSON, JOHN S. TOKARSKI, JOANN STRNAD, ADRIAN: "Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 62, no. 20, 24 October 2019 (2019-10-24), US , pages 1 - 23, XP055629848, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b00444 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023181075A1 (fr) * 2022-03-24 2023-09-28 Dr. Reddy's Laboratories Limited Dispersions solides amorphes de deucravacitinib et leurs procédés de préparation

Also Published As

Publication number Publication date
CN116615200A (zh) 2023-08-18

Similar Documents

Publication Publication Date Title
US10493158B2 (en) Pharmaceutical compositions for the treatment of inflammatory disorders
JP5932848B2 (ja) アモルファス（５−フルオロ−２−メチル−３−キノリン−２−イルメチル−インドール−１−イル）−酢酸
CN110054624B (zh) 盐酸小檗碱与咖啡酸共晶物及制备方法和其组合物与用途
JP7295833B2 (ja) Ｏｌｉｇ２活性の阻害
KR20180086497A (ko) sGC 자극제를 포함하는 고체 분산물
WO2021088672A1 (fr) Composition contenant un hydrate de bésylate de legoamodipine et sa méthode de préparation
WO2022083649A1 (fr) Forme cristalline d'un dérivé pyridazinique
CN110041326B (zh) 盐酸小檗碱与反丁烯二酸共晶物及制备方法和其组合物与用途
WO2015176591A1 (fr) Sels de betrixaban, procede de preparation et utilisation de ceux-ci
CN115300513A (zh) 一种包含杂环类shp2抑制剂的组合物及其用途
EP4029863A1 (fr) Maléate de dérivé d'éther d'alcool nicotinylique, forme cristalline de celui-ci et utilisation associée
WO2022258059A1 (fr) Composition pharmaceutique, préparation, procédé de préparation et utilisation de cette dernière
US20220048918A1 (en) Pkc inhibitor solid state forms
WO2023050104A1 (fr) Dérivé d'indoline, son procédé de préparation, composition pharmaceutique et utilisation
US20160090385A1 (en) Crystalline forms of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboximide for the treatment of myeloproliferative disorders
WO2023125275A1 (fr) Sel de composé aminopyrimidine et son utilisation
WO2022144042A1 (fr) Forme cristalline de tas-116, son procédé de préparation, sa composition pharmaceutique et son utilisation
US11795180B2 (en) Formulation of a pan-JAK inhibitor
TWI815472B (zh) 一種激酶抑制劑的鹽晶型和自由鹼晶型
WO2023280090A1 (fr) Composition pharmaceutique, son procédé de préparation et son application
WO2020029903A1 (fr) Sel d'inhibiteur du vhc et son procédé de préparation
WO2018130226A1 (fr) Nouvelle forme cristalline de riociguat, procédé de préparation et utilisation correspondants
TW202333739A (zh) 二肽基肽酶1抑制劑多晶型物及其製備方法和用途
CN115477647A (zh) 小檗碱富马酸盐晶型及其制备方法和其组合物与应用
CN118221650A (zh) 氟取代的吲唑化合物的晶型及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21882064

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202180069237.3

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21882064

Country of ref document: EP

Kind code of ref document: A1